PTC Therapeutics (PTCT) said Wednesday it agreed to sell its Rare Pediatric Disease Priority Review Voucher for $150 million, upon completion of the transaction.
The voucher was granted on Nov. 13 along with the US Food and Drug Administration's approval of Kebilidi to treat children and adults with AADC deficiency.
Priority review vouchers are awarded by the FDA to incentivize the drug development for rare pediatric diseases.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.